AI Consensus Investment Thesis
GSK (GSK) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY2,055 GBX
+9.5%+13.8% incl. dividends5-Year
BUY2,650 GBX
+41.2%+71.7% incl. dividendsLatest flagship insight
Specialty Pipeline Acceleration Shields Biopharma Cash Flows Against Imminent Generic Patent Cliff
There is high consensus that specialty biopharma expansion and structural cost-reduction programs will defend operating margins against upcoming late-decade patent expirations. Robust free cash flow and resolved litigation provide defensive stability, though divergence persists regarding pipeline replacement velocity and debt servicing costs during generic erosion.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Machiavelli (Insider), Elon Musk (Visionary), Warren Buffett (Value Purist), Ray Dalio (Strategist), Superintelligence (Anthropologist), Michael Burry (Vulture), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in GSK at the forecast anchor (2026-09-18): $16,952 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 4.0% net dividend yield for GSK.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in GBX; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (GBX) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 1,923.28 | +2.44% | +2.44% | Third-quarter results confirm robust specialty medicine growth and seasonal vaccine distribution. Initial cost savings from Accelerate Growth and regulatory clarity on acquired oncology assets support positive sentiment, enabling modest valuation multiple expansion despite elevated interest rates. |
| Q1 2027 | 1,968.88 | +2.37% | +4.87% | Full-year 2026 financial reporting delivers core operating profit at the guided upper bound alongside dividend reaffirmation. Commercial traction for long-acting HIV regimens and resolved litigation liabilities encourage institutional capital accumulation, driving steady equity appreciation. |
| Q2 2027 | 2,016.89 | +2.44% | +7.42% | First-quarter disclosures showcase strong international vaccine expansion and oncology adoption, offsetting mature respiratory pricing pressure. Resilient operating cash flow comfortably absorbs integration costs and debt servicing, maintaining positive share price momentum across European markets. |
| Q3 2027 | 2,055.11 | +1.90% | +9.46% | Interim Phase III readouts for bepirovirsen and depemokimab provide positive clinical validation. Although summer vaccine seasonality and elevated clinical trial expenditure temporarily moderate operating leverage, underlying equity sentiment remains well defended by defensive prescription cash flows. |
| Q4 2027 | 2,098.56 | +2.11% | +11.77% | Accelerate Growth achieves its initial annualized cost reduction milestones, buffering operating margins. Expanding patient adoption of Cabenuva and Apretude reinforces visibility ahead of upcoming patent transitions, driving defensive institutional inflows into year-end portfolio positioning. |
| Q1 2028 | 2,131.34 | +1.56% | +13.52% | Full-year 2027 results confirm mid-single-digit constant currency revenue expansion and healthy free cash flow conversion. Management provides confident guidance for the impending patent cliff, reassuring income-focused investors and sustaining stable valuation multiples. |
| Q2 2028 | 2,102.92 | -1.33% | +12.01% | Initial US loss of exclusivity on oral dolutegravir prompts predictable headline sentiment caution and targeted generic discounting. However, accelerated conversion to long-acting regimens and rising oncology revenues cushion the financial impact, preventing severe multiple de-rating. |
| Q3 2028 | 2,132.96 | +1.43% | +13.61% | Second-quarter metrics confirm that specialty medicines and depemokimab uptake effectively mitigate oral HIV generic erosion. Realized restructuring savings protect core operating profitability, prompting value-oriented buyers to step in and stabilize quoted equity valuations. |
| Q4 2028 | 2,177.45 | +2.09% | +15.98% | Cumulative annualized restructuring savings surpass one billion pounds, structurally protecting operating margins against generic pricing pressure. Regulatory approvals for new oncology indications expand commercial visibility, reigniting positive share momentum heading into the fiscal year-end. |
| Q1 2029 | 2,205.86 | +1.30% | +17.49% | Full-year 2028 financial delivery demonstrates that core operating profits remained resilient through early generic competition. Evidence of effective patent cliff absorption dismantles the terminal value-trap narrative, driving institutional short covering and solid multiple expansion. |
| Q2 2029 | 2,231.91 | +1.18% | +18.88% | European dolutegravir patent expirations take effect but encounter minimal commercial disruption due to established injectable market share. Continued scaling of acquired lung cancer therapies preserves group gross margins, maintaining orderly, positive share price discovery. |
| Q3 2029 | 2,262.31 | +1.36% | +20.50% | Mid-year clinical updates showcase favorable registrational endpoints across respiratory biologics and next-generation mRNA vaccines. High-margin specialty turnover exceeds half of group sales, proving management's strategic portfolio transformation and supporting steady equity compounding. |
| Q4 2029 | 2,317.47 | +2.44% | +23.43% | Full realization of the targeted £1.9 billion annual cost savings permanently optimizes operational overhead. Surging cash generation from commercial oncology blockbusters accelerates balance-sheet deleveraging, reinforcing investor confidence in corporate capital allocation execution. |
| Q1 2030 | 2,369.33 | +2.24% | +26.20% | Full-year 2029 reporting corroborates margin defense above thirty percent despite peak generic dolutegravir exposure. The board signals an impending resumption of share repurchases, prompting broad institutional accumulation and sustained valuation multiple expansion. |
| Q2 2030 | 2,414.69 | +1.91% | +28.61% | Commercial rollout of next-generation combination therapies broadens leadership in specialty infectious diseases. Strong operating leverage from rationalized biomanufacturing enhances net income conversion, supporting steady equity gains across global healthcare portfolios. |
| Q3 2030 | 2,460.45 | +1.90% | +31.05% | Pivotal Phase III data for ultra-long-acting HIV prevention regimens cement multi-year therapeutic dominance, neutralizing generic copycats. Market sentiment responds to structural innovation capability, driving multiple re-rating toward international specialty pharmaceutical peer medians. |
| Q4 2030 | 2,510.60 | +2.04% | +33.72% | Specialty medicines and vaccines contribute over two-thirds of group revenue, while balance-sheet deleveraging concludes successfully. Surging free cash flow comfortably covers progressive dividend increases and active buybacks, driving robust year-end equity performance. |
| Q1 2031 | 2,562.49 | +2.07% | +36.48% | Full-year 2030 audited financials confirm group revenue firmly tracking toward long-term corporate turnover milestones. Core earnings expand at high single digits, validating multi-year margin resilience and driving comprehensive sell-side earnings estimate upgrades. |
| Q2 2031 | 2,605.68 | +1.69% | +38.78% | Expanding international market penetration across emerging vaccine markets sustains durable top-line compounding. With the patent cliff fully absorbed, defensive asset qualities and dependable cash distributions attract steady institutional capital inflows. |
| Q3 2031 | 2,650.10 | +1.70% | +41.15% | Final forecast period consolidates the five-year transformation into a high-margin specialty biopharma compounder. The market closes the historical valuation discount, pricing the equity at full parity with global pharmaceutical leaders to complete the investment cycle. |
The fundamental investment case centers on an operational bridge: high-margin Specialty Medicines expansion and £1.9 billion in structural cost extraction via the Accelerate Growth initiative insulate consolidated operating profitability as oral dolutegravir approaches loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry between 2028 and 2030. Valuation remains anchored at a pronounced discount to global biopharmaceutical peers, supported by a resilient free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry and post-Zantac balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry normalization. The pivotal risk is whether clinical reinvestment and £7.1 billion in net acquisition debt sufficiently yield commercial blockbusters before generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry permanently compresses legacy ViiV Healthcare earnings.
Key insights
- Long-acting antiretroviral conversions structurally transform transactional pill demand into sticky outpatient administration networks, preserving unit pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry despite small-molecule oral generic availability.
- Aggressive external business development elevates balance-sheet leverage, shifting intermediate capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry priorities away from discretionary share repurchases toward non-discretionary debt amortization and clinical funding.
- Restructuring savings function primarily as an operational buffer against statutory payer price concessions rather than delivering net margin windfalls to equity holders.
The company is building a bridge to replace older blockbuster medicines before their patents expire late this decade. Strong sales from specialty medicines and vaccines, paired with major cost cuts, help protect overall company profits. Meanwhile, healthy cash generation and settled lawsuits keep the financial foundation steady. However, higher debt from acquiring new cancer treatments means the business must manage spending carefully while launching new products.
Key insights
- Long-acting injectable therapies keep patients loyal, protecting prescription revenues even when cheaper generic daily pills enter the market.
- Recent takeover debt requires cash to be used for debt repayments rather than funding massive share repurchases.
- Large operational cost cuts serve mainly to balance out government pricing pressure on older medications.
Deep Dive
External market commentary and prevailing sell-side coverage treat the company as an entrenched, low-multiple value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry. The dominant public belief assumes that the looming 2028 dolutegravir patent expiration will trigger an insurmountable earnings contraction that maturing specialty drugs cannot offset. Investors remain heavily anchored on historical litigation concerns, post-pandemic vaccine slowdowns, and clinical trial attrition, pricing the equity at an enduring valuation discount to international peers.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? External market commentary and prevailing sell-side coverage treat the company as an entrenched, low-multiple value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry. The dominant public belief assumes that the looming 2028 dolutegravir patent expiration will trigger an insurmountable earnings contraction that maturing specialty drugs cannot offset. Investors remain heavily anchored on historical litigation concerns, post-pandemic vaccine slowdowns, and clinical trial attrition, pricing the equity at an enduring valuation discount to international peers.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates fundamental value, creating observable underpricing across the equity. The market misinterprets the approaching dolutegravir patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry as an unmitigated revenue collapse, overlooking that rapid patient migration toward long-acting injectable regimens and high-margin oncology launches actively builds an earnings replacement moat. Furthermore, consensus models fail to credit the £1.9 billion Accelerate Growth restructuring, which defends core operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above 30%. The strongest challenge remains clinical trial execution risk and elevated debt servicing costsdebt servicing costsInterest and related payments required to maintain outstanding debt obligations.View full glossary entry from recent acquisitions.
Repricing Catalyst
What could make the market recognize and close that gap? Pivotal Phase III clinical trial readouts and regulatory decisions across 2026 and 2027 represent the primary catalyst cluster forcing market repricing. Accelerated commercial uptake for depemokimab alongside registrational progress for bepirovirsen and acquired lung cancer assets will demonstrate tangible pipeline replacement power. If consecutive quarterly reports verify that specialty volume gains and restructuring savings defend operating profit ahead of 2028 patent expiries, institutional investors will be forced to dismantle the punitive value-trap discount.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Perspectives agree that fear and patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry anxiety dominate positioning. However, assessments diverge on whether sentiment has fully stabilized or is entering growing awareness, creating timing tension around whether multiple re-rating precedes or follows tangible 2028 generic revenue prints.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop is a net favorable setup. Inelastic prescription demand for essential therapies and vaccines protects revenue against stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry. While restrictive interest rates elevate debt servicing expenses following recent acquisitions, robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry cushions financing burdens, positioning the company as an attractive defensive haven against broader equity volatility.
Advisor Disagreement
What do our AI Advisors disagree about most? The central debate revolves around the velocity of pipeline replacement versus the severity of oral dolutegravir generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry. Optimistic perspectives assume that rapid long-acting HIV conversions, specialty oncology scaling, and £1.9 billion in restructuring savings will seamlessly offset patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry, justifying significant multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Conversely, skeptical viewpoints argue that clinical attrition, £7.1 billion in acquisition debt, and US statutory pricing caps will leave an unfillable earnings void, keeping the equity trapped at discounted multiples. Auditing reported core operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry through the initial 2028 generic launch window will empirically resolve this economic tension.
Base-Case Forces
Event Risk ScoreLow22/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Long-acting HIV franchise regimen conversion | Competitive Positioning | +18% | +18% | ViiV Healthcare is systematically transitioning patients from daily oral dolutegravir to long-acting injectables Cabenuva and Apretude. This clinical migration creates formidable switching barriers, preserving premium pricing and extending specialty franchise revenue beyond upcoming oral patent expiries. Sustained double-digit adoption protects high-margin operating cash flows and defends group earnings. |
| Specialty oncology and immunology portfolio expansion | Innovation And Product | +18% | +22% | Accelerating momentum across specialty oncology therapies, including Jemperli, Ojjaara, and acquired targeted kinase inhibitors, establishes a vital replacement growth pillar. Complemented by the launch of ultra-long-acting respiratory biologic depemokimab, these proprietary treatments generate superior gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry exceeding 75%, effectively replacing mature medicine revenue decay and driving core earnings compounding. |
| Accelerate Growth restructuring margin protection | Operational Efficiency | +13% | +16% | Management's Accelerate Growth initiative extracts £1.9 billion in net annual structural operating savings by 2029 across administrative and procurement infrastructure. By trimming overhead, this program cushions operating profitability against loss-of-exclusivity margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry. Captured efficiencies self-fund twenty concurrent Phase III trial campaigns, ensuring resilient core earnings per share delivery. |
| Adult vaccine franchise demographic expansion | Competitive Positioning | +11% | +11% | Aging global demographics provide a persistent secular tailwind for core immunization assets Shingrix and Arexvy. Expanding international market distribution and broader adult cohort recommendations leverage proprietary adjuvant technology. High biologic manufacturing hurdles and entrenched government procurement relationships generate defensible, high-margin cash streams that insulate top-line revenue from broader macroeconomic cycles. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Dolutegravir loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry cliff | Competitive Positioning | -17% | -18% | Approaching primary patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry for oral dolutegravir between 2028 and 2030 threaten ViiV Healthcare's highest-margin revenue generator. Exposed oral combinations face aggressive generic price discounting across core Western jurisdictions. While long-acting formulations provide meaningful mitigation, small-molecule volume defection will inevitably contract franchise gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and impose an unavoidable top-line earnings drag. |
| US statutory drug price negotiation | Regulatory | -9.0% | -9.0% | Medicare price negotiation protocols and statutory rebate caps under federal healthcare legislation systematically compress net realized prices across mature respiratory and specialty medications. Mandatory manufacturer discounts restrict domestic commercial pricing flexibility, widening gross-to-net deductions. This institutional payer pushback suppresses realized operating cash flows, dampening revenue trajectory in the most lucrative pharmaceutical market. |
| Leverage expansion from debt-financed acquisitions | Capital Allocation | -8.0% | -8.0% | Funding the £7.1 billion net cash acquisition of Nuvalent elevated group debt into an environment of restrictive global interest rates. Elevated debt servicing obligations absorb significant operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry, moderating free cash conversion. This financial commitment temporarily constrains discretionary share repurchase capacity, forcing management to prioritize balance-sheet deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry over enhanced capital distributions. |
| Vaccine competitive crowding and regulatory constriction | Sector And Industry | -8.0% | -9.0% | Arexvy and Shingrix confront decelerating growth curves as initial high-risk patient cohorts mature across Western healthcare markets. Narrowed advisory committee recommendations and intensifying rivalry from alternative RSV vaccines restrict volume expansion. Heightened commercial marketing and detailing outlays compress vaccine segment operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, capping prospective incremental returns on invested commercial capital. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal Phase III oncology and immunology trial failure | 29% | -22% | Unexpected clinical failures or safety halts across flagship late-stage programs, including acquired lung cancer assets or Blenrep confirmatory trials, would destroy post-cliff growth projections. Following the camlipixant write-down, major pipeline setbacks would trigger multi-billion-pound non-cash impairment chargesimpairment chargesAccounting write-downs required when the carrying value of an asset exceeds its fair market value.View full glossary entry. The inability to replace expiring dolutegravir revenues would expose the company to severe generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry, prompting sharp valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry de-rating. |
| Premature dolutegravir patent invalidation rulings | 23% | -21% | Adverse judicial decisions in Hatch-Waxman patent litigation invalidating secondary crystalline or combination formulation patents could trigger generic dolutegravir launches up to two years ahead of schedule. An accelerated loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry would evaporate high-margin oral revenues before long-acting regimens and specialty pipelines attain commercial scale. The sudden cash-flow void would impair dividend coverage and trigger abrupt institutional equity liquidation. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Bepirovirsen chronic hepatitis B functional cure approval | 34% | +24% | Definitive Phase III clinical readouts establishing unprecedented functional cure efficacy for antisense oligonucleotide bepirovirsen could secure expedited global regulatory approvals by 2028. Successfully targeting a global chronic hepatitis B population exceeding 250 million patients would create a multi-billion-pound commercial franchise. This breakthrough would completely dismantle dolutegravir patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry concerns, catalyzing rapid multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and substantial upward revisions to outer-year earnings. |
| Ultra-long-acting HIV self-administration monopoly | 29% | +21% | Clinical breakthroughs enabling four-month and six-month self-administered subcutaneous HIV maintenance regimens before 2029 would establish insurmountable therapeutic dominance. Converting patients to biannual home maintenance would preempt oral generic competition entirely and accelerate pre-exposure prophylaxis market adoption. The resulting high-margin cash flows would secure long-term franchise longevity, prompting sovereign and institutional re-rating toward premium global biopharma valuations. |
Company Financial Analysis
GSK Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The company's core business continues to perform solidly, driven by strong prescription sales in specialty medicines and adult vaccines. In fiscal 2025, revenue reached £32.7 billion with underlying operating profit expanding steadily. This operational momentum confirms that day-to-day healthcare demand remains reliable and growing. However, headline reported profits experience periodic swings from non-cash accounting adjustments, including a £1.3 billion write-down on a discontinued trial medicine. These paper charges temporarily obscure robust underlying cash generation. With normalized annual free cash flow remaining near £6 billion, the business generates ample liquidity to self-fund its operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | GBP 32.7B | GBP 5.7B | GBP 6B |
| 2024 | GBP 31.4B | GBP 2.6B | GBP 3.6B |
| 2023 | GBP 30.3B | GBP 4.9B | GBP 4.4B |
| 2022 | GBP 29.3B | GBP 15B | GBP 5.1B |
| 2021 | GBP 24.7B | GBP 4.4B | GBP 5B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 13.0x | TTM | Native | GBX / GBP |
| 2024 | 21.7x | TTM | Native | GBX / GBP |
| 2023 | 12.1x | TTM | Native | GBX / GBP |
| 2022 | 3.9x | Annual | Native | GBX / GBP |
| 2021 | 9.6x | Annual | Native | GBX / GBP |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability has structurally improved because the company sells an increasing proportion of complex specialty therapies and proprietary vaccines. Gross profit margins expanded above 72% in fiscal 2025, reflecting pricing strength and manufacturing efficiencies that help counteract rising supply chain expenses. To defend profitability against future generic competition, management is executing a restructuring plan targeting £1.9 billion in annual cost savings by 2029. By streamlining administration and commercial operations, these efficiencies ensure core operating margins remain stable near 30% even as older medications face lower generic prices.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | GBP 7.2B | 21.9% | 17.5% |
| 2024 | GBP 5.7B | 18.0% | 8.2% |
| 2023 | GBP 7B | 23.1% | 16.2% |
| 2022 | GBP 6.7B | 22.8% | 51.0% |
| 2021 | GBP 5.4B | 21.9% | 17.8% |
Balance sheet and leverage
AI Review
The company's financial foundation has grown considerably safer following the resolution of nearly all major state lawsuits over heartburn medication. Debt levels remain prudent relative to the company's size, and annual earnings cover interest payments more than eleven times over, easily satisfying credit rating agencies. Recent debt issued to finance the £7.1 billion net acquisition of a cancer specialist has increased total borrowing. Nevertheless, strong annual operating cash flow approaching £9 billion comfortably supports regular interest obligations. This financial resilience allows management to protect dividend distributions while gradually paying down acquisition debt.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | GBP 17.7B | GBP 3.2B | GBP 14.6B net debt | 0.82x |
| 2024 | GBP 17B | GBP 3.7B | GBP 13.3B net debt | 0.78x |
| 2023 | GBP 18B | GBP 5B | GBP 15.3B net debt | 0.88x |
| 2022 | GBP 21B | GBP 7.7B | GBP 17.5B net debt | 0.91x |
| 2021 | GBP 24.2B | GBP 4.1B | GBP 20.1B net debt | 0.79x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has deliberately shifted its investment focus away from physical factories and toward discovering and developing new medicines. While physical facility spending consumed just over 4% of revenue, research and development spending surged past £7.5 billion in fiscal 2025 to advance over twenty late-stage clinical programs. This elevated research intensity represents an essential strategic commitment to invent replacement treatments before older drugs lose patent protection. In addition, the company committed substantial capital to acquire targeted lung cancer therapies. While this aggressive reinvestment temporarily limits surplus cash, it constructs high-barrier intellectual property essential for future growth.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | GBP 1.3B | GBP 7.5B |
| 2024 | GBP 3B | GBP 5.5B |
| 2023 | GBP 2.3B | GBP 5.2B |
| 2022 | GBP 2.3B | GBP 4.8B |
| 2021 | GBP 2.9B | GBP 4.4B |
Quarterly Forecast Scenarios
GSK Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in GBX; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (GBX) | Base case (GBX) | Bull case (GBX) | S&P 500 benchmark (USD) | FX (GBP/USD) |
|---|---|---|---|---|---|
| 1,915 GBX | 1,923 GBX | 1,934 GBX | $750.26 | 1.3237 | |
| 1,895 GBX | 1,977 GBX | 2,011 GBX | $736.44 | 1.3096 | |
| 1,971 GBX | 2,022 GBX | 2,072 GBX | $743.40 | 1.3087 | |
| 2,012 GBX | 2,061 GBX | 2,113 GBX | $755.15 | 1.3116 | |
| 2,052 GBX | 2,102 GBX | 2,197 GBX | $776.22 | 1.3089 | |
| 2,011 GBX | 2,132 GBX | 2,263 GBX | $787.13 | 1.3071 | |
| 1,931 GBX | 2,112 GBX | 2,218 GBX | $802.83 | 1.3128 | |
| 1,873 GBX | 2,140 GBX | 2,262 GBX | $812.05 | 1.3158 | |
| 1,873 GBX | 2,185 GBX | 2,353 GBX | $839.18 | 1.3139 | |
| 1,892 GBX | 2,222 GBX | 2,471 GBX | $850.50 | 1.3090 | |
| 1,854 GBX | 2,245 GBX | 2,495 GBX | $872.39 | 1.3128 | |
| 1,835 GBX | 2,276 GBX | 2,570 GBX | $885.51 | 1.3138 | |
| 1,872 GBX | 2,332 GBX | 2,647 GBX | $909.56 | 1.3168 | |
| 1,891 GBX | 2,386 GBX | 2,753 GBX | $916.13 | 1.3159 | |
| 1,929 GBX | 2,431 GBX | 2,836 GBX | $936.51 | 1.3216 | |
| 1,948 GBX | 2,476 GBX | 2,893 GBX | $947.34 | 1.3218 | |
| 1,967 GBX | 2,526 GBX | 2,979 GBX | $969.59 | 1.3189 | |
| 2,007 GBX | 2,580 GBX | 3,069 GBX | $979.99 | 1.3198 | |
| 2,027 GBX | 2,623 GBX | 3,130 GBX | $999.60 | 1.3236 | |
| 2,047 GBX | 2,666 GBX | 3,193 GBX | $1,012 | 1.3227 |
Behind the synthesis
How each opinion shapes the consensus
Across the independent submissions, an empirically grounded consensus confirms that robust cash generation, structural Zantac litigation de-risking, and favorable product mix in Specialty Medicines provide strong near-term earnings resilience. However, correlated assumptions emerge regarding the seamless replacement of dolutegravir cash flows, where several reports aggressively model rapid multiple expansion despite unavoidable generic pricing deflation between 2028 and 2030. The strongest credible contrarian case highlights that late-stage clinical attrition and elevated debt service from the debt-funded Nuvalent acquisition could coincide with generic erosion, squeezing free cash flow. Reports demonstrating forensic accounting discipline—explicitly modeling Nuvalent interest dilution, statutory US drug price negotiation impacts, and the net delivery of the £1.9 billion Accelerate Growth restructuring—are awarded top relative weights. Conversely, reports projecting aggressive multiple expansion above 16 times earnings without addressing patent cliff reinvestment costs receive downward adjustments to prevent correlated over-optimism.
Universal Investor AI
The Polymath
GPT-6 AstraThe highest quality submission, providing unmatched empirical rigor across verified financial statements, Nuvalent dilution sequencing, and CMS drug price negotiation mechanics. Its balanced thesis rejects speculative multiple expansion, anchoring returns in cash generation and disciplined reinvestment, justifying the top relative weight.
Universal Investor AI
The Polymath
Opus 5Distinguished by exceptional forensic fidelity, this analysis integrates SEC filings, bond issuances for Nuvalent, and the expiration of US trade and tariff agreements. Its measured baseline projection properly links financing costs to per-share metrics, justifying a high relative weight.
Universal Investor AI
The Polymath
Gemini 3.8 FlashA highly rigorous submission grounded in primary filings, this report cogently evaluates the Accelerate Growth cost-out versus oral HIV generic erosion. It balances pipeline optionality with realistic clinical attrition. A higher weight reflects thorough evidence synthesis and sound causal consistency.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashThis report systematically evaluates the central macro and micro trade-offs, particularly how the three-year restructuring initiative shields operating margins against generic pricing pressure. A well-earned above-average weight rewards explicit mechanism tracing, realistic rate sensitivity, and rigorous cash-flow scrutiny.
Michael Burry AI
The Vulture
Gemini 3.8 FlashOffering a disciplined balance-sheet assessment, this analysis highlights the 7.5% free cash flow yield and conservative valuation floor. It captures post-Zantac settlement clarity while prudently evaluating late-stage clinical trials. A solid weight rewards causal rigor and defensible cash-flow expectations.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProviding an incisive evaluation of post-Zantac legal de-risking and long-acting HIV switching kinetics, this report appropriately models the margin-protective effect of Accelerate Growth. A robust weight reflects causal consistency, high evidence quality, and balanced assessment of Phase III development risks.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashExhibiting solid grounding in clinical trial milestones and commercial uptake dynamics for depemokimab and Blenrep, this analysis avoids extreme multiple assumptions. A solid allocation reflects disciplined examination of operational leverage and realistic appraisal of competitive threats in respiratory biologics.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThis report details operational mechanics under Luke Miels and the Nuvalent integration, but relies on somewhat optimistic multiple re-rating assumptions despite looming dolutegravir loss of exclusivity. A moderate weight reflects solid clinical analysis tempered by aggressive terminal valuation projections.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThe analysis effectively captures the patient transition from oral dolutegravir to long-acting Cabenuva and Apretude. However, it slightly understates the near-term interest drag from acquisition debt and statutory US pricing headwinds. A standard allocation is justified by coherent free cash flow modeling.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis analysis presents the strongest contrarian case, modeling severe oral HIV revenue loss and capital misallocation risks. While its skepticism regarding pipeline replacement velocity is valuable, its extreme multiple compression overlooks verified restructuring savings and long-acting conversion defensibility, warranting a measured conservative weighting.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashFocusing on durable owner earnings and wide biological moats in vaccines, this analysis provides sound long-term reasoning. However, it somewhat minimizes statutory US pricing pressures and post-acquisition debt absorption. A calibrated baseline weight reflects strong capital return analysis balanced against execution uncertainties.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis report accurately identifies the market's overreaction to patent expiries relative to non-discretionary healthcare demand. However, its factor impacts and path assumptions are somewhat generic across the middle forecast quarters. A standard weight captures its valuation floor insights while avoiding correlated overemphasis.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashWhile offering detailed pipeline tracking for bepirovirsen and Blenrep, this perspective incorporates an excessively optimistic expansion trajectory toward 57% gains that minimizes generic pricing destruction. A trimmed weight prevents double-counting bullish assumptions unsupported by conservative payer and reimbursement realities.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThis perspective offers valuable forensic tracking of restructuring milestones, but projects aggressive multiple expansion and a 70% return path that underweights dolutegravir margin contraction. A reduced weight incorporates its operational insights while discounting its outlier valuation scenario.
Research Provenance
References & Context
This GSK consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 81 deduplicated sources retained for this batch.
- 01Selected Drugs and Negotiated Prices | CMScms.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 03GSK plc - Form 6-K - FY2026sec.gov
- 04GSK plc - Form 6-K - FY2026sec.gov
- 05GSK plc - Form 6-K - FY2026sec.gov
- 06GSK plc - Form 6-K - FY2026sec.gov
- 07GSK stock gains on USD 750 million blood cancer drug deal and analyst upgradesad-hoc-news.de
- 08GSK stock steady as RBC starts coverage and Q2 2026 figures reshape outlookad-hoc-news.de
- 09GSK PLC Earnings - Analysis & Highlights for Q1 2026alpha-sense.com
- 10GSK Names Luke Miels as Next Chief Executive Officer | Contract Pharmacontractpharma.com
- 11GSK Q2 Earnings Call Highlights - Daily Politicaldailypolitical.com
- 12GSK plc (GSK): SWOT Analysis [Apr-2026 Updated]dcf-analysis.com
- 13Which blockbuster is GSK gunning for next? CEO Miels is looking to oncologyfiercebiotech.com
- 14GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...finance.yahoo.com
- 152025 Annual Reportgsk.com
And 66 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: GBP, GBX, USD (quote GBX; primary reporting GBP; converted/valuation USD; normalization GBP).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.